Handelsavisen
prelaunch
Companies Healthcare BOUL.ST
BO
BOUL.ST Nasdaq Stockholm Advanced Medical Equipment & Technology

Boule Diagnostics AB

kr3,80
Open in Charts → Attach watcher ⌖
SEK
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
147,6M SEK
P/E
EV / Rev
0,3x
Div yield
0,00 %
Op margin
1,0 %
ROE
-0,3 %
Net margin
-1,2 %
Debt / equity
0,37
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Boule Diagnostics AB develops and sells advanced medical equipment and technology for diagnostic applications, primarily in the healthcare sector.

Business. Boule Diagnostics AB (BOUL.ST) is a healthcare company operating in the Advanced Medical Equipment & Technology industry. The firm is headquartered in Sweden and is primarily listed on the Nasdaq Stockholm exchange. Specific details regarding its operating segments and geographic revenue mix are not provided in the available data.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
Generated · model-assisted
Sell-side consensus
HOLD1 analysts
0 buy1 hold0 sell
Avg 12m price target

Analyst recommendations

1 analysts · consensus Hold
Buy0
Hold1
Sell0
12-month price target
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Hold
1 analysts · indicative
Ownership
not yet wired
Profitability
-0,3 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning BOUL.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to BOUL.ST. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Boule Diagnostics AB (BOUL.ST) is a healthcare company operating in the Advanced Medical Equipment & Technology industry. The firm is headquartered in Sweden and is primarily listed on the Nasdaq Stockholm exchange. Specific details regarding its operating segments and geographic revenue mix are not provided in the available data.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryAdvanced Medical Equipment & Technology
    AI synthesis
    GENERATED

    Boule Diagnostics has a market price of 3.52 SEK and a market capitalization of 136,692,526.08 SEK, with a price-to-book ratio of 0.28 and a price-to-tangible-book ratio of 0.28, indicating a significant discount to its book value. The company's enterprise value to EBITDA ratio is 203.78, and its enterprise value to revenue is 2.08, suggesting a low valuation relative to its revenue but a high multiple on earnings. The company's liquidity position is characterized by a current ratio of 1.23 and a cash and equivalents balance of 34.7 million SEK, which is insufficient to cover its long-term debt of 183.3 million SEK.

    Profitability metrics show a return on equity of -0.32% and a return on assets of -0.20%, indicating that the company is not generating returns for its shareholders or assets. The operating margin is 1.02%, and the net margin is -0.12%, reflecting a narrow operating profit and a net loss. These figures are below the industry median for profitability, suggesting that Boule Diagnostics is underperforming its peers in terms of generating returns.

    The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification, which increases its exposure to market-specific risks. The capital expenditure of -3.7 million SEK indicates that the company is not investing in new assets, which may limit its growth potential. The company's free cash flow of 1.1 million SEK is minimal, suggesting that it has limited capacity to fund operations or growth initiatives.

    Looking ahead, the company's revenue is expected to remain flat, with no significant growth anticipated in the next fiscal year. The company's net loss of 1.6 million SEK and a negative return on equity suggest that it is not currently generating value for shareholders. The risk assessment indicates a medium liquidity risk and a low dilution risk, but the company's net cash position is negative after subtracting total debt, which could impact its financial flexibility.

    Recent events, including the company's financial performance and analyst estimates, suggest that the company is facing challenges in generating consistent earnings and maintaining a positive return on investment. The company's mean recommendation from analysts is a "Hold," with no strong buy or buy ratings, indicating a cautious outlook from the investment community. The last actual EPS was -0.10 SEK, significantly below the mean EPS estimate of 0.82 SEK, highlighting the company's earnings shortfall.

    Key takeaways
    • Boule Diagnostics is trading at a significant discount to book value, with a price-to-book ratio of 0.28.
    • The company's profitability metrics, including a return on equity of -0.32%, indicate poor performance relative to its peers.
    • The company's revenue is concentrated in a single business segment, increasing its exposure to market-specific risks.
    • The company's free cash flow is minimal, suggesting limited capacity to fund operations or growth initiatives.
    • Analysts have a cautious outlook, with a mean recommendation of "Hold" and no strong buy or buy ratings.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 3

    Operating income surged 106% year-over-year to SEK 20.8 million, signaling a strong operational recovery from the prior fiscal year's losses.

    Free cash flow improved by 105.4% to SEK 15.3 million, demonstrating a significant restoration of cash generation capabilities.

    Return on equity of -0.3% is significantly better than the cohort median of -4.7%, suggesting relatively efficient use of shareholder capital.

    BEAR CASE · 4

    Long-term debt increased to SEK 223.8 million, representing a rising leverage burden amidst declining revenue trends.

    The company faces high credit risk, posing potential challenges for future financing and operational stability.

    Debt-to-equity ratio of 0.37 is significantly higher than the cohort median of 0.06, indicating elevated financial leverage.

    Cash conversion of -16.44% falls in the bottom quartile of the cohort, highlighting poor efficiency in converting earnings to cash.

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-04-28
    Q1 2026 · Quarter highlights

    Revenue kr 489.7M, +333,8% YoY.

    Revenuekr 489.7M+333,8 % YoY
    Operating income
    Net income
    Free cash flow
    EPS
    Operating cash flowkr 9.9M+226,9 % YoY
    Financials
    Income statement
    Revenuekr 489.7M
    Gross profit
    Operating income
    Net income
    Balance sheet
    Total assets
    Total liabilitieskr 296.4M
    Total equitykr 171.5M
    Cash & equivalentskr 18.5M
    Long-term debtkr 222.0M
    Cash flow
    Operating cash flowkr 9.9M
    CapEx-kr 200.0k
    Free cash flow
    SBC
    Highlights
    • Revenue kr 489.7M, +333,8% YoY

    Valuation TTM

    Market price
    kr3,80
    Market cap
    kr136.7M
    Enterprise value
    kr285.3M
    P/E
    Non-GAAP P/E
    EV / Revenue
    0.3x
    EV / Op income
    12.8x
    EV / OCF
    10.8x
    P / B
    0.3x
    P / Tangible book
    0.3x
    Tangible book
    kr496.2M
    Net cash
    -kr148.6M
    Current ratio
    1.2
    Debt / equity
    0.4
    ROA
    -0.2%
    ROE
    -0.3%
    Cash conversion
    -1644.0%
    CapEx / revenue
    -2.7%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    0,82
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    1
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-16 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate0,82
    Revenueno estimateno estimate453,0M SEK
    Operating incomeno estimateno estimate50,0M SEK
    Full-year consensus mean (period as reported by source) · consensus in SEK. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution1 analysts
    Strong buy0
    Buy0
    Hold1
    Sell0
    Strong sell0
    Operating income · consensus50,0M SEK
    EPS surprise
    −112,2 %
    reported vs consensus · miss
    Revenue surprise
    +8,1 %
    reported vs consensus · beat

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin1,0 %Above median
    Net Margin-1,2 %Above median
    ROE-0,3 %Above median
    Capex / Rev-2,7 %Above median
    D/E0,37Below median
    Cash Conv-16,44Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Ev To Operating Cash Flow
      enterprise_value / operating_cash_flow
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    Source documents
    • Boule Diagnostics AB Market data — financials · 2026-05-27
    • Boule Diagnostics AB Market data — analyst estimates · 2026-05-27
    • Boule Diagnostics AB Market data — ESG · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    BOUL.STCanonical
    Nasdaq Stockholm · SEK

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-20 00:43 UTCANALYSTAnalyst coverage initiated
    2026-04-28 07:11 UTCEARNINGSQuarterly results — Q1 2026 Revenue SEK 489.7M
    2026-02-11 08:21 UTCEARNINGSQuarterly results — Q4 2025 Revenue SEK 120.3M · Net SEK 1.6M
    2026-02-11 08:21 UTCEARNINGSAnnual results — FY 2026 Revenue SEK 489.7M · Net SEK -3.8M
    2025-10-24 07:22 UTCEARNINGSQuarterly results — Q3 2025 Revenue SEK 127.2M · Net SEK 10.9M
    2025-07-18 07:13 UTCEARNINGSQuarterly results — Q2 2025 Revenue SEK 129.3M · Net SEK -5.7M
    2025-04-28 07:05 UTCEARNINGSQuarterly results — Q1 2025 Revenue SEK 112.9M · Net SEK -10.3M
    2025-02-11 07:07 UTCEARNINGSQuarterly results — Q4 2024 Revenue SEK 143.3M · Net SEK -75.6M
    2025-02-11 07:07 UTCEARNINGSAnnual results — FY 2025 Revenue SEK 558.5M · Net SEK -296.6M
    2024-10-25 07:25 UTCEARNINGSQuarterly results — Q3 2024 Revenue SEK 130.4M · Net SEK -229.2M
    2024-07-22 06:34 UTCEARNINGSQuarterly results — Q2 2024 Revenue SEK 137.0M · Net SEK -1.6M
    2024-02-06 06:36 UTCEARNINGSAnnual results — FY 2024 Revenue SEK 571.3M · Net SEK 25.0M
    2023-02-02 06:38 UTCEARNINGSAnnual results — FY 2023 Revenue SEK 548.1M · Net SEK 12.7M
    2022-02-03 07:38 UTCEARNINGSAnnual results — FY 2022 Revenue SEK 463.3M · Net SEK 23.3M
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage